FDA Ranks DNA Cancer Detector as Safe Tool
Published Date: 5/9/2025
Rule
Summary
The FDA is officially putting the DNA-based test that checks for tiny amounts of leftover cancer cells in blood cancers into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while making it simpler for companies to get it to patients faster. The new rules started on May 9, 2025, and could speed up access to this important test without extra costs.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
MRD Test Moved to Class II
The FDA officially classified the DNA-based test to measure minimal residual disease (MRD) in hematological malignancies as Class II (special controls), effective May 9, 2025, with the classification applicable on September 28, 2018. As a Class II device, it is subject to premarket notification under section 510(k) rather than automatic Class III premarket approval.
Enables Faster Market Entry for Future Tests
FDA stated that when a device is classified into Class II via the De Novo process, that device can serve as a predicate for future devices, allowing other sponsors to use the less-burdensome 510(k) process instead of submitting a De Novo request or a premarket approval application. This change was noted as a way to reduce regulatory burdens and enhance access to innovation.
Required Test Validation and Reporting Standards
The final order establishes special controls requiring detailed design verification and validation studies, labeling that lists the clinical hematopoietic malignancy, specimen type, and specific DNA regions detected, and requires the device output to include an estimated MRD frequency plus an uncertainty range (for example: "MRD = 1.2 x 10-5 [Range = 0.8 x 10-6 to 2.0 x 10-5]").
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08137, New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs approved in early 2025, making sure everything is clear and up-to-date. This affects drug makers, vets, and pet owners by confirming which new medicines are officially good to go. The changes kick in right away on May 9, 2025, with no extra costs but better info and transparency for everyone.
Next: 2025-08144, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Measure Non-Microbial Analytes To Aid in the Detection and Identification of Localized Human Infections
The FDA is officially putting devices that detect and measure non-microbial markers to find localized infections into a safer, more manageable category called Class II. This change, effective May 9, 2025, means these devices will face fewer regulatory hurdles, making it easier and faster for patients to get access to new, helpful infection-detecting tools. Companies making these devices will now follow special safety rules but avoid the toughest approval process, saving time and money.